Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study
Authors' conclusion
Tirzepatide treatment was associated with improved HRQoL compared to placebo in people with overweight or obesity. Higher percentages of weight reduction were associated with greater improvements.
Study context
- Population
- Participants with obesity or overweight in SURMOUNT-1
- Comparison
- Tirzepatide vs placebo; and by categorical degree of weight reduction
- Primary endpoint
- Changes in Patient-reported Outcomes (PROs) of Health-related Quality of Life (HRQoL) (IWQOL-Lite-CT, SF-36v2, EQ-5D-5L)
Primary result
As reported in the abstract
PRO scores (HRQoL)
- All tirzepatide groups showed significant improvements in PRO scores vs placebo
- Consistent trend of incremental PRO improvement with greater weight reduction, starting from ≥5%
Further findings
| Outcome | Values |
|---|---|
| Change from baseline in PRO scores, ≥20% weight reduction (greatest changes) · baseline to week 72 | ≥20% 4.60 · SF-36v2 Physical Component Summary 4.60 · SF-36v2 Mental Component Summary 0.80 · IWQOL-Lite CT Total score 24.7 |
- Change from baseline in PRO scores, ≥20% weight reduction (greatest changes): value = SF-36v2 Physical Component Summary
PRO improvement by baseline physical (PGIS) and psychosocial (PHQ-2) limitations
- Those with baseline physical and psychosocial limitations improved more than those without
Original publication
Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study. Diabetes Obes Metab. Published 4 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →